Post job

Competitor Summary. See how Allogene Therapeutics compares to its main competitors:

  • Atara Biotherapeutics has the most employees (578).
  • The oldest company is BioTime, founded in 1990.
Work at Allogene Therapeutics?
Share your experience

Allogene Therapeutics vs competitors

CompanyFounding dateZippia scoreHeadquarters# of LocationsRevenueEmployees
2017
3.6
South San Francisco, CA2$95,000289
2007
4.5
San Diego, CA1$13.6M104
2012
4.4
South San Francisco, CA6$128.9M578
2014
4.2
San Diego, CA1$64.7M200
1990
3.4
Alameda, CA1$3.4M101
2006
3.8
Emeryville, CA1$500,00050
2008
4.0
Philadelphia, PA1$178.0M452
2015
4.1
Cambridge, MA1$661.1M118
Cabaletta Bio
2017
4.0
Philadelphia, PA1$1.6M20
2008
4.0
Parkton, NC2$82.5M148
Arcellx
2015
4.0
Gaithersburg, MD1$107.9M1

Rate how well Allogene Therapeutics differentiates itself from its competitors.

Zippia waving zebra

Allogene Therapeutics salaries vs competitors

Compare Allogene Therapeutics salaries vs competitors

CompanyAverage salaryHourly salarySalary score
Allogene Therapeutics
$108,396$52.11-

Compare Allogene Therapeutics job title salaries vs competitors

CompanyHighest salaryHourly salary
Allogene Therapeutics
$120,060$57.72
Adaptimmune
$137,091$65.91
Fate Therapeutics
$125,579$60.37
BioTime
$124,287$59.75
Atara Biotherapeutics
$122,711$59.00
Cabaletta Bio
$122,569$58.93
G1 Therapeutics
$121,655$58.49
Eureka Therapeutics
$121,189$58.26
TCR² Therapeutics
$119,647$57.52
Arcellx
$119,633$57.52
Poseida Therapeutics
$118,967$57.20

Do you work at Allogene Therapeutics?

Does Allogene Therapeutics effectively differentiate itself from competitors?

Allogene Therapeutics jobs

0

Allogene Therapeutics revenue vs competitors

Allogene Therapeutics revenue is $95.0K. Among it's competitors, the company with the highest revenue is TCR² Therapeutics, $661.1M . The company with the lowest revenue is Eureka Therapeutics, $500.0K.

Allogene Therapeutics and similar companies CEOs

CEOBio
Brian Culley
BioTime

Experienced public company CEO determined to leave the world a healthier place than when he arrived by developing new treatments for serious diseases and conditions.

J. Scott Wolchko
Fate Therapeutics

J Scott Wolchko are a President/CEO/COO at FATE THERAPEUTICS INC and Board Member at FATE THERAPEUTICS INC. They have worked as Chief Financial Officer at Bocada and VP:Operations/CFO at FATE THERAPEUTICS INC. J studied at University of Virginia and Alpha Omega Alpha Medical Honor Society.

Jack Bailey
G1 Therapeutics

Jack Bailey is a Corporate Advisor at Eshelman Institute for Innovation, Chief Executive Officer at G1 Therapeutics Inc, and Vice President at ELI LILLY & CO and is based in Chapel Hill, North Carolina. He has worked as Senior VP:US Account Markets at ELI LILLY & CO, Consultant at GSK, and President:US Pharmaceuticals at GSK. Jack works or has worked as BOARD MEMBER at Joint Commission Resources, BOARD MEMBER at Triangle Global Health Consortium Inc, and BOARD MEMBER at National Pharmaceutical Council Executive Committee. He attended Hobart and William Smith Colleges, University of North Carolina at Chapel Hill, and UNC Kenan-Flagler Business School.

Adrian Rawcliffe (Ad)
Adaptimmune

Adrian (Ad) Rawcliffe is a Chief Executive Officer at Adaptimmune, Senior VP:Worldwide Bus Dev at GSK, and Board Member at WaVe Life Sciences Pte Ltd and is based in Philadelphia, Pennsylvania. He has worked as Chartered Accountant at Pricewaterhouse Coopers (PwC), President/Managing Partner at Sr One, and Chief Financial Officer at Adaptimmune Therapeutics Plc. Adrian (Ad) studied at Durham University between 1990 and 1993 and Masters of Awkward.

Rami Elghandour
Arcellx

Rami joined Arcellx in 2021 and serves as the Chairman and Chief Executive Officer. Most recently, Rami served as President and CEO of Nevro, where he joined in 2012. Under his leadership, Nevro grew from a small private company to a public company approaching $400m in revenue and a leader in neuromodulation. Prior to Nevro, Rami was an investor with Johnson & Johnson Development Corporation (JJDC), where he led several investments including Nevro’s Series B Financing and served on the Board of Directors of several private companies including Nevro’s. Prior to joining JJDC, Rami was a Design Engineer for Advanced Neuromodulation Systems, Inc. where he led firmware design and development on several implantable spinal cord stimulators. Rami earned recognition as an EY Entrepreneur of the Year, as one of the top CEOs in the U.S. and as one of the top CEOs for women and diversity. He is a recipient of the Bill Campbell award by Watermark for his influence, impact, and advocacy in promoting women and women’s issues. Rami received a MBA from the Wharton School of the University of Pennsylvania and holds a BS in Electrical and Computer Engineering from Rutgers University School of Engineering.

Allogene Therapeutics competitors FAQs

Search for jobs